3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
13
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Endometrial Neoplasms
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Pheochromocytoma
1
Pathologic Complete Response
1
Paraganglioma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
talazoparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled